FDA OKs new drug for type 2 diabetes

A drug derived from lizard saliva has been approved by U.S. regulators to treat Diabetes in patients who have not responded to other treatments, the drug’s developers, Eli Lilly and Co. and Amylin Pharmaceuticals Inc., said on Friday.

The drug, exenatide, to be sold under the brand name Byetta, was approved by the U.S. Food and Drug Administration as an add-on therapy for patients with type 2 diabetes—the most common form—whose blood sugar is not sufficiently controlled by two other treatments. The FDA did not approve the drug as a stand-alone treatment.

The drug is made from the saliva of the Gila monster lizard, which lives in the Arizona desert and eats just four times a year. It is the first of a new class of drugs known as incretin mimetics. It mimics hormones released in the human gut in response to food that help regulate glucose levels.

About 18 million people in the United States have diabetes, or 6.2 percent of the population. Diabetics are unable to produce enough insulin or cannot process their insulin properly, resulting in dangerously high blood-sugar levels, which can lead to Heart disease, Blindness and amputations if not treated.

RELATED STORIES:
Immune therapy stops diabetes in mouse study   Diabetics Show Alarming Increase in Morbid Obesity   Psoriasis linked to diabetes, hypertension   Forearm test not good for checking blood sugar   Imagining helps in remembering medication - study   Diabetes ups cancer death risk   Men and women differ in risk for type 1 diabetes   Diabetes linked to reduced risk of prostate cancer   Cholesterol drug prevents heart disease in diabetics   Avandia linked with severe lipid abnormalities   Obese Kids At Risk For Diabetes   Xenical may boost insulin in diabetics

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]